MedTrace Logo

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

NCT03401840 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-02-13

No results posted yet for this study

Summary

The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal and oral cavity cancer with high risk margins.

Conditions

  • Head and Neck Neoplasms

Interventions

RADIATION

postoperative hypofractionated stereotactic radiotherapy

total dose of 36Gy in 6 fractions over 11-13 days

Sponsors & Collaborators

  • GORTEC

    collaborator OTHER

  • Centre Jean Perrin

    lead OTHER

Principal Investigators

  • Julian BIAU · Centre Jean Perrin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-23
Primary Completion
2023-09-28
Completion
2023-09-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401840 on ClinicalTrials.gov